Precigen announces full fda approval of papzimeos (zopapogene imadenovec-drba), the first and only approved therapy for the treatment of adults with recurrent respiratory papillomatosis

Papzimeos approval marks a historic milestone for the rrp patient community as the first and only fda-approved therapy for the treatment of adults with rrp papzimeos received full approval from the fda for the treatment of adults with rrp; a confirmatory clinical trial is no longer required  rrp is a rare, debilitating, and potentially life-threatening disease caused by chronic hpv 6 or hpv 11 infection, which results in recurrent benign tumors in the respiratory tract; rrp affects an estimated 27,000 adult patients in the us papzimeos is a non-replicating adenoviral vector-based immunotherapy designed to generate an immune response directed against papilloma cells expressing hpv 6/11—the first and only approved therapy to treat the root cause of rrp precigen will host a conference call on monday, august 18 at 8:00 am et germantown, md , aug. 15, 2025 /prnewswire/ -- precigen, inc. (nasdaq: pgen), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced that the us food and drug administration (fda) has approved papzimeos™ (zopapogene imadenovec-drba) for the treatment of adults with recurrent respiratory papillomatosis (rrp). papzimeos is the first and only fda-approved therapy for the treatment of adults with rrp.
PGEN Ratings Summary
PGEN Quant Ranking